Oncolytics Biotech, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oncolytics Biotech, Inc.
Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.
The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.
Accelerated initial public listings, multi-million dollar deals and hot investment fund influxes fuel an already record-setting July for biotech fundraising in China.
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.